Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Net Margin (2016 - 2025)

Cytosorbents' Net Margin history spans 15 years, with the latest figure at 59.53% for Q4 2025.

  • Quarterly results put Net Margin at 59.53% for Q4 2025, up 2316.0% from a year ago — trailing twelve months through Dec 2025 was 22.12% (up 3684.0% YoY), and the annual figure for FY2025 was 22.12%, up 3609.0%.
  • Net Margin for Q4 2025 was 59.53% at Cytosorbents, down from 33.42% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 20.25% in Q2 2025 to a low of 150.42% in Q3 2022.
  • The 5-year median for Net Margin is 65.47% (2023), against an average of 62.91%.
  • Peak annual rise in Net Margin hit 7816bps in 2022, while the deepest fall reached -8916bps in 2022.
  • Year by year, Net Margin stood at 86.32% in 2021, then surged by 91bps to 8.16% in 2022, then plummeted by -725bps to 67.31% in 2023, then fell by -23bps to 82.69% in 2024, then increased by 28bps to 59.53% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 59.53%, 33.42%, and 20.25% for Q4 2025, Q3 2025, and Q2 2025 respectively.